With a $220,000 grant from FRAXA Research Foundation over 3 years, Dr. Iryna Ethell from the University of California at Riverside studied the regulation of dendritic structure by matrix metalloproteinases and other extracellular signaling pathways. This work identified a major treatment strategy for Fragile X with the available MMP-9 inhibitor, minocycline.
Read moreBilousova, Tina
Tina Bilousova, PhD, Associate Project Scientist at the University of California-Los Angeles, does biomedical research with a focus in synaptic variations in neurodevelopmental and neurodegenerative disorders.